Inflammatory Bowel Disease

A purely dichotomous understanding of whether to start treatment for patients who have IBD with anti-TNF agents is becoming an outdated view.

Even the most experienced and skilled gastroenterologists in the country are struggling to make science-based decisions in this area.

A straightforward discussion drove toward attendees toward the more current understanding of the clinical and genetic overlap between the 2 major forms of IBD.

Extraintestinal manifestations of inflammatory bowel disease affect the musculoskeletal, dermatologic, ocular, renal and pulmonary systems.

They are similar chronic inflammatory diseases with causes unknown, and recent clinical and genetic evidence supports an intertwined pathogenic relationship.

Patients with ulcerative colitis and Crohn’s disease typically don’t receive preventive services at the same rate as general medical patients. Vaccination is a key area of confusion.

(AUDIO) According to the Centers for Disease Control, more than one-third of US adults are obese. The CDC also estimates that as many as 1.4 million Americans suffer from inflammatory bowel disorder. So is there a link?

The location (pretibial surface) of this ulcer, its visibly rolled undermined border, and severe pain are all typical of pyoderma gangrenosum, which is typically associated with inflammatory bowel disease, rheumatoid arthritis, and hematologic malignancies.

Is the increased risk of IBD due to pollution, a too-clean home, or antibiotics? Or none of the above?

An association between non-steroidal anti-inflammatory drugs and these two inflammatory bowel disorders has long been suspected but not, until now, documented.